M
Mohammed Almubarak
Researcher at West Virginia University
Publications - 24
Citations - 275
Mohammed Almubarak is an academic researcher from West Virginia University. The author has contributed to research in topics: Lung cancer & Bevacizumab. The author has an hindex of 6, co-authored 22 publications receiving 192 citations.
Papers
More filters
Journal ArticleDOI
Guideline-concordant lung cancer care and associated health outcomes among elderly patients in the United States.
Pramit Nadpara,Sundareswaran Suresh Madhavan,Cindy Tworek,Usha Sambamoorthi,Michael Hendryx,Mohammed Almubarak +5 more
TL;DR: There is a critical need to address disparities in receipt of guideline-concordant lung cancer care among elderly in the US, and underutilization of these services is a concern.
Journal ArticleDOI
Can Positron Emission Tomography Be Used as a Staging Tool for Small-Cell Lung Cancer?
Mridula Vinjamuri,Michael Craig,Annette Campbell-Fontaine,Mohammed Almubarak,Naresh C. Gupta,John S. Rogers +5 more
TL;DR: Positron emission tomography is potentially useful for accurate initial staging of SCLC and can ensure that a patient's disease is not overstaged by CT scan, which might result in denied potentially curative treatment for limited-stage SCLCs.
Journal ArticleDOI
Phase 1b/2, open label, multicenter, study of the combination of SD-101 and pembrolizumab in patients with advanced melanoma who are naïve to anti-PD-1 therapy.
Mohammed M. Milhem,Georgina V. Long,Christopher J. Hoimes,Asim Amin,Christopher D. Lao,Robert M. Conry,Jason P. Hunt,Gregory A. Daniels,Mohammed Almubarak,Montaser Shaheen,Theresa Medina,Minal A. Barve,Sarwan Bishnoi,E Abdi,Michael Chisamore,Biao Xing,Albert Candia,Erick Gamelin,Robert Janssen,Antoni Ribas +19 more
TL;DR: The safety and preliminary efficacy of the combination of SD-101 and pembrolizumab is assessed, with promising results in patients with recurrent central giant cell granuloma.
Journal ArticleDOI
Phase 1b/2, open label, multicenter study of intratumoral SD-101 in combination with pembrolizumab in anti-PD-1 treatment naïve patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC).
Ezra E.W. Cohen,Lisle Nabell,Deborah J.L. Wong,Terry A. Day,Gregory A. Daniels,Mohammed M. Milhem,Sanjeev Deva,Michael B. Jameson,Orlando Guntinas-Lichius,Mohammed Almubarak,Robert Matthew Strother,Eric D. Whitman,Michael Chisamore,Cynthia Chinedu Obiozor,Teresa Bagulho,Albert Candia,Erick Gamelin,Robert Janssen,Alain Algazi +18 more
TL;DR: SD-101, a synthetic CpG-ODN agonist of TLR9, stimulates dendritic cells to release IFN-alpha and mature into antigen presenting cells - activating T cell anti-tumor responses.
Journal ArticleDOI
Efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinoma
Steven G. Waguespack,Alexander Drilon,Jessica Lin,Marcia S. Brose,Ray McDermott,Mohammed Almubarak,Jessica Bauman,Michela Casanova,Anuradha Krishnamurthy,Shivaani Kummar,Serge Leyvraz,Do Youn Oh,Keunchil Park,Davendra Sohal,Eric J. Sherman,Ricarda Norenberg,Josh D. Silvertown,Nicoletta Brega,David Hohn,Maria E. Cabanillas +19 more
TL;DR: The highly selective TRK inhibitor larotrectinib showed durable antitumour efficacy and a favourable safety profile in patients with TRK fusion-positive thyroid carcinoma, and show that patients with advanced non-medullary thyroid carcinomas who may require systemic therapy could be considered for testing for gene fusions by next-generation sequencing.